Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 166.1 Million USD | 2.88% |
| 2022 | 161.46 Million USD | 2.65% |
| 2021 | 157.29 Million EUR | -0.57% |
| 2020 | 158.2 Million EUR | 3137.11% |
| 2019 | 4.88 Million EUR | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 71.44 Million EUR | 65.71% |
| 2016 | 43.11 Million EUR | 214.09% |
| 2015 | 13.72 Million EUR | 1069.75% |
| 2014 | 1.17 Million EUR | -29.59% |
| 2013 | 1.66 Million EUR | -35.73% |
| 2012 | 2.59 Million EUR | -9.66% |
| 2011 | 2.87 Million EUR | 0.0% |
| 2010 | - EUR | -100.0% |
| 2009 | 2.56 Million EUR | -95.13% |
| 2008 | 52.57 Million EUR | -35.06% |
| 2007 | 80.96 Million USD | 0.0% |
| 2006 | - EUR | -100.0% |
| 2005 | 165.81 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 98.35 Million USD | 0.0% |
| 2024 Q3 | 92.09 Million USD | 5.47% |
| 2024 Q1 | 28.43 Million USD | -100.0% |
| 2023 Q1 | 164.65 Million USD | 1.98% |
| 2023 Q3 | 158.46 Million USD | -3.66% |
| 2023 Q2 | 164.48 Million USD | -0.1% |
| 2023 FY | 166.1 Million USD | 2.88% |
| 2023 Q4 | 136.48 Million USD | -13.87% |
| 2022 Q3 | 135.23 Million USD | -6.66% |
| 2022 Q4 | 161.46 Million USD | 19.4% |
| 2022 FY | 161.46 Million USD | 2.65% |
| 2022 Q1 | 153.46 Million USD | 10.45% |
| 2022 Q2 | 144.88 Million USD | -5.59% |
| 2021 Q2 | 145.43 Million EUR | 3.02% |
| 2021 Q3 | 140.84 Million EUR | -3.16% |
| 2021 Q4 | 138.93 Million EUR | -1.35% |
| 2021 FY | 157.29 Million EUR | -0.57% |
| 2021 Q1 | 141.16 Million EUR | -10.63% |
| 2020 Q1 | 138.54 Million EUR | 2731.55% |
| 2020 FY | 158.2 Million EUR | 3137.11% |
| 2020 Q4 | 157.95 Million EUR | 4.87% |
| 2020 Q3 | 150.62 Million EUR | 5.16% |
| 2020 Q2 | 143.23 Million EUR | 3.38% |
| 2019 Q4 | 4.89 Million EUR | -81.38% |
| 2019 Q1 | 40.69 Million EUR | -5.09% |
| 2019 Q2 | 34.11 Million EUR | -16.17% |
| 2019 FY | 4.88 Million EUR | 0.0% |
| 2019 Q3 | 26.27 Million EUR | -22.99% |
| 2018 Q3 | 48.35 Million EUR | -13.06% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | 42.88 Million USD | -11.33% |
| 2018 Q2 | 55.62 Million EUR | -10.43% |
| 2018 Q1 | 62.09 Million EUR | -13.08% |
| 2017 Q1 | 36.5 Million EUR | -15.32% |
| 2017 FY | 71.44 Million EUR | 65.71% |
| 2017 Q4 | 71.44 Million EUR | -14.63% |
| 2017 Q3 | 83.68 Million EUR | -7.63% |
| 2017 Q2 | 90.6 Million EUR | 148.16% |
| 2016 Q3 | 10.51 Million EUR | -8.6% |
| 2016 Q1 | 12.59 Million EUR | -8.23% |
| 2016 Q2 | 11.5 Million EUR | -8.67% |
| 2016 Q4 | 43.11 Million EUR | 310.0% |
| 2016 FY | 43.11 Million EUR | 214.09% |
| 2015 FY | 13.72 Million EUR | 1069.75% |
| 2015 Q3 | 16.1 Million EUR | 1504.57% |
| 2015 Q4 | 13.72 Million EUR | -14.78% |
| 2015 Q2 | 1 Million EUR | 1.53% |
| 2015 Q1 | 988.7 Thousand EUR | -15.74% |
| 2014 FY | 1.17 Million EUR | -29.59% |
| 2014 Q4 | 1.17 Million EUR | -14.05% |
| 2014 Q3 | 1.36 Million EUR | -15.9% |
| 2014 Q2 | 1.62 Million EUR | 3.73% |
| 2014 Q1 | 1.56 Million EUR | -6.1% |
| 2013 Q2 | 2.41 Million EUR | 3.48% |
| 2013 Q4 | 1.66 Million EUR | -34.75% |
| 2013 FY | 1.66 Million EUR | -35.73% |
| 2013 Q3 | 2.55 Million EUR | 5.56% |
| 2013 Q1 | 2.33 Million EUR | -9.83% |
| 2012 Q3 | 2.72 Million EUR | 0.0% |
| 2012 Q1 | 2.69 Million EUR | -6.0% |
| 2012 Q4 | 2.59 Million EUR | -5.0% |
| 2012 FY | 2.59 Million EUR | -9.66% |
| 2011 FY | 2.87 Million EUR | 0.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q4 | 2.87 Million EUR | 0.0% |
| 2010 Q2 | 2.00 EUR | 0.0% |
| 2010 FY | - EUR | -100.0% |
| 2010 Q1 | - EUR | -100.0% |
| 2010 Q4 | - EUR | -100.0% |
| 2010 Q3 | 2.00 EUR | 0.0% |
| 2009 FY | 2.56 Million EUR | -95.13% |
| 2009 Q4 | 2.56 Million EUR | 0.0% |
| 2008 FY | 52.57 Million EUR | -35.06% |
| 2007 FY | 80.96 Million USD | 0.0% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | 165.81 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -2076212.5% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -9362.09% |
| Qrons Inc. | 80 Thousand USD | -207531.25% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -717.768% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -96906.95% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -694.419% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -283152.618% |
| Mesoblast Limited | 100.29 Million USD | -65.617% |
| Marizyme, Inc. | 667.12 Thousand USD | -24798.483% |
| Genus plc | 228.2 Million USD | 27.211% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -3013415.965% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -7416.063% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -11739.83% |
| IMV Inc. | 27.39 Million USD | -506.254% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -2961.008% |
| MultiCell Technologies, Inc. | 36.43 USD | -455956529.152% |
| ONE Bio Corp. | 592.19 Thousand USD | -27948.896% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -198.686% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -7362.04% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -13422.491% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -29850.955% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -656467.453% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -8649.423% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -51485.404% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 98.522% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -110636.667% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -101057.09% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -981.835% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -3727570.557% |
| Genscript Biotech Corporation | 287.12 Million USD | 42.15% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -131414.149% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -72342.878% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -72216.721% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -1909.983% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -62431.293% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -15611272.18% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -110922.364% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -110922.364% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -117704.965% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -2024.116% |
| SYBLEU INC | 300 Thousand USD | -55268.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -44908.928% |
| International Stem Cell Corporation | 445 Thousand USD | -37226.966% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -1938.098% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -36246.827% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -14207.063% |
| PureTech Health plc | 18.25 Million USD | -810.164% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -110636.667% |
| IXICO plc | 275 Thousand USD | -60301.818% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -1303.032% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -531.362% |
| CSL Limited | 11.23 Billion USD | 98.522% |
| Cellectis S.A. | 36.21 Million USD | -358.712% |